• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

UCI prostate cancer project awarded $1.2 million by state precision medicine initiative

Bioengineer by Bioengineer
November 15, 2016
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Matt Herp / ADA

Irvine, Calif., Nov. 15, 2016 — University of California, Irvine health policy researchers have been awarded $1.2 million by the California Initiative to Advance Precision Medicine to develop more effective ways for prostate cancer patients and their physicians to customize treatment.

Dr. Sheldon Greenfield and Sherrie H. Kaplan, co-executive directors of UCI's Health Policy Research Institute, will lead the project. It was one of six funded today by the state initiative, which was created in 2015 to provide the infrastructure and resources necessary to advance precision medicine-oriented data, tools and applications in California.

"This grant represents an exciting opportunity to link patient-reported disease burden with tumor biomarkers to evaluate the effectiveness of prostate cancer treatment," said Greenfield, the Donald Bren Professor of Medicine at UCI. "We envision that study results will help doctors and patients tailor treatment based on a composite picture of the patient's illness, tumor biology and personal circumstances."

Prostate cancer is the most common cancer in men, with more than 200,000 new cases diagnosed each year in the U.S. It is the second-leading cause of cancer death in males and affects roughly 1 in 7 of them over their lifetime.

The project will focus on improving risk predictions, including both the benefits and the potential harms of different treatment strategies for early-stage prostate cancer. Among the most pressing challenges that face physicians who care for men with prostate cancer is evaluating one's potential benefit from treatment. As part of the two-year clinical study, prostate cancer patients will be given a detailed questionnaire that features 25 questions addressing myriad existing health issues to help determine the aggressiveness of treatment.

The final prognosis will be based on detailed patient characteristics, such as sociodemographic factors, health status and disease management burden, combined with traditional prostate cancer severity indicators and established genomic identifiers.

Greenfield expects that 600 patients from five Southern California-area hospitals will be enrolled. Along with the UCI personnel, the team – which has had considerable prior experience collaborating on research projects – will include investigators and patients from UCLA, Cedars-Sinai Medical Center, the Veterans Affairs Greater Los Angeles Healthcare System and the Veterans Affairs Long Beach Healthcare System.

"Right now, the evidence supports treatment decisions for the average patient. This study will give doctors much better data on which to base recommendations for individual patients," said Kaplan, adding that this approach will be applicable to other cancers and chronic diseases.

The six projects funded today by the California Initiative to Advance Precision Medicine aim to promote customized healthcare by using data-driven tools and analysis to develop new diagnostics, therapies and insights into disease. The winning teams will join forces to utilize data across research, clinical, environmental and population health settings to better diagnose, treat, manage and prevent disease.

Projects based at UC Davis, UC San Francisco, Children's Hospital Oakland Research Institute, Cedars-Sinai Medical Center and Sutter Health were also awarded grants.

The California Initiative to Advance Precision Medicine was launched by Gov. Jerry Brown last year and received additional funding in fiscal 2016-17. UC Health and UC San Francisco host the initiative with the Governor's Office of Planning & Research.

###

About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 30,000 students and offers 192 degree programs. It's located in one of the world's safest and most economically vibrant communities and is Orange County's second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit http://www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.

Media Contact

Tom Vasich
[email protected]
949-824-6455
@UCIrvine

http://www.uci.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Woodpeckers Grunt Like Tennis Stars While Drilling, Scientists Discover

November 6, 2025
Bonding Strengths: Hydroxyapatite Coated Gutta Percha Insights

Bonding Strengths: Hydroxyapatite Coated Gutta Percha Insights

November 6, 2025

Phospholipid Scramblases Drive Tumor Growth Via PS

November 6, 2025

Estrogen Receptor Protects Hippocampal Neurons from Amyloid β

November 6, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1301 shares
    Share 520 Tweet 325
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    313 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    206 shares
    Share 82 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    138 shares
    Share 55 Tweet 35

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Woodpeckers Grunt Like Tennis Stars While Drilling, Scientists Discover

Bonding Strengths: Hydroxyapatite Coated Gutta Percha Insights

Phospholipid Scramblases Drive Tumor Growth Via PS

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.